Literature DB >> 26931741

HOXB13 protein expression in metastatic lesions is a promising marker for prostate origin.

Justine Varinot1, Adéline Furudoï2, Sarah Drouin3, Véronique Phe3, Raphaele Renard Penna4, Morgan Roupret3, Marc-Olivier Bitker3, Olivier Cussenot3, Eva Compérat2.   

Abstract

The HOXB13 gene is a member of the homeobox gene family, and prostate development depends on HOXB13 function. HOXB13 is a very sensitive and specific marker of prostate tissue and prostate cancer. When the origin of a tumor in a resection specimen or in biopsy material is unclear, it allows determining the prostate as the primary. Our aim was to determine whether HOXB13 has similar sensitivity for determining prostate origin of lymph node and bone metastases. We retrieved cases of lymph node and bone metastases of histologically confirmed prostate cancer (PCa) and selected lymph node metastases of urothelial carcinoma (UCa). A panel of antibodies against HOXB13, PSA, ERG, Androgen receptors, p504S, p63, GATA-3, CK7, and Uroplakin 2 and 3 was tested on these tissue samples. Two pathologists analysed and scored staining as either 0 (negative) or + (positive). The selected cohort consisted of 74 cases of lymph node and 15 of bone metastases of PCa and 15 of lymph node metastases of UCa. HOXB13 was expressed in 93 % of lymph node and in 33 % of bone metastases of PCa. All lymph node metastases of UCa were negative. Sensitivity of HOXB13 as a marker for prostate origin in lymph node metastases was 93 % and for bone metastases 33 %. Inter-observer variability in assessment of staining was good, as only two (1.9 %) of lymph node metastasis of PCa were discordant. HOXB13 is a useful marker for prostate origin when doubt exists regarding the site of the primary of a metastatic lesion. On bone metastases, HOXB13 immunohistochemistry performed less well, probably due to the use of tissue decalcification.

Entities:  

Keywords:  HOXB13; Immunohistochemistry; Metastasis; Prostate cancer

Mesh:

Substances:

Year:  2016        PMID: 26931741     DOI: 10.1007/s00428-016-1917-x

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  12 in total

1.  NKX3.1 as a marker of prostatic origin in metastatic tumors.

Authors:  Bora Gurel; Tehmina Z Ali; Elizabeth A Montgomery; Shahnaz Begum; Jessica Hicks; Michael Goggins; Charles G Eberhart; Douglas P Clark; Charles J Bieberich; Jonathan I Epstein; Angelo M De Marzo
Journal:  Am J Surg Pathol       Date:  2010-08       Impact factor: 6.394

2.  Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.

Authors:  Jonathan I Epstein; Lars Egevad; Peter A Humphrey; Rodolfo Montironi
Journal:  Am J Surg Pathol       Date:  2014-08       Impact factor: 6.394

3.  Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference.

Authors:  Mahul B Amin; Kiril Trpkov; Antonio Lopez-Beltran; David Grignon
Journal:  Am J Surg Pathol       Date:  2014-08       Impact factor: 6.394

4.  Germline mutations in HOXB13 and prostate-cancer risk.

Authors:  Charles M Ewing; Anna M Ray; Ethan M Lange; Kimberly A Zuhlke; Christiane M Robbins; Waibhav D Tembe; Kathleen E Wiley; Sarah D Isaacs; Dorhyun Johng; Yunfei Wang; Chris Bizon; Guifang Yan; Marta Gielzak; Alan W Partin; Vijayalakshmi Shanmugam; Tyler Izatt; Shripad Sinari; David W Craig; S Lilly Zheng; Patrick C Walsh; James E Montie; Jianfeng Xu; John D Carpten; William B Isaacs; Kathleen A Cooney
Journal:  N Engl J Med       Date:  2012-01-12       Impact factor: 91.245

5.  Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.

Authors:  Jun Luo; Shan Zha; Wesley R Gage; Thomas A Dunn; Jessica L Hicks; Christina J Bennett; Charles M Ewing; Elizabeth A Platz; Sacha Ferdinandusse; Ronald J Wanders; Jeffrey M Trent; William B Isaacs; Angelo M De Marzo
Journal:  Cancer Res       Date:  2002-04-15       Impact factor: 12.701

6.  Utility of p63 immunohistochemical stain in differentiating urothelial carcinomas from adenocarcinomas of prostate.

Authors:  Nasir Ud Din; Asim Qureshi; Samina Mansoor
Journal:  Indian J Pathol Microbiol       Date:  2011 Jan-Mar       Impact factor: 0.740

7.  Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.

Authors:  Ai-Ying Chuang; Angelo M DeMarzo; Robert W Veltri; Rajni B Sharma; Charles J Bieberich; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2007-08       Impact factor: 6.394

8.  HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin.

Authors:  Justine Varinot; Olivier Cussenot; Morgan Roupret; Pierre Conort; Marc-Olivier Bitker; Emmanuel Chartier-Kastler; Liang Cheng; Eva Compérat
Journal:  Virchows Arch       Date:  2013-10-22       Impact factor: 4.064

9.  Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression.

Authors:  Florence Jourdan; Nicole Sebbagh; Eva Comperat; Najat Mourra; Antoine Flahault; Sylviane Olschwang; Alex Duval; Richard Hamelin; Jean-François Flejou
Journal:  Virchows Arch       Date:  2003-06-07       Impact factor: 4.064

10.  HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey.

Authors:  Steven C Smith; Nallasivam Palanisamy; Kimberly A Zuhlke; Anna M Johnson; Javed Siddiqui; Arul M Chinnaiyan; Lakshmi P Kunju; Kathleen A Cooney; Scott A Tomlins
Journal:  Am J Surg Pathol       Date:  2014-05       Impact factor: 6.394

View more
  6 in total

Review 1.  Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies.

Authors:  Emma E van der Toom; Haley D Axelrod; Jean J de la Rosette; Theo M de Reijke; Kenneth J Pienta; Kenneth C Valkenburg
Journal:  Nat Rev Urol       Date:  2019-01       Impact factor: 14.432

2.  HOXB13 expression in metastatic prostate cancer.

Authors:  Valeria Barresi; Antonio Ieni; Luca Reggiani Bonetti; Giovanni Tuccari
Journal:  Virchows Arch       Date:  2016-04-28       Impact factor: 4.064

3.  HOXB13 expression in metastatic prostate cancer.

Authors:  Justine Varinot; Eva Comperat
Journal:  Virchows Arch       Date:  2016-05-16       Impact factor: 4.064

Review 4.  HOXB13 a useful marker in pleomorphic giant cell adenocarcinoma of the prostate: a case report and review of the literature.

Authors:  Laura Larnaudie; Eva Compérat; Pierre Conort; Justine Varinot
Journal:  Virchows Arch       Date:  2017-05-08       Impact factor: 4.064

5.  Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.

Authors:  Ilka Kristiansen; Carsten Stephan; Klaus Jung; Manfred Dietel; Anja Rieger; Yuri Tolkach; Glen Kristiansen
Journal:  Int J Mol Sci       Date:  2017-05-29       Impact factor: 5.923

6.  ACK1-AR and AR-HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers.

Authors:  Eric H Kim; Dengfeng Cao; Nupam P Mahajan; Gerald L Andriole; Kiran Mahajan
Journal:  NAR Cancer       Date:  2020-08-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.